DNTH
Dianthus Therapeutics Inc
Dianthus Therapeutics Inc historical holders
total: 1
Polen Capital Management Dianthus Therapeutics Inc transactions over time
- Total transactions:
- 2
- New positions:
- 1
- Added:
- 1
- Held since:
- 2026 Q1
- Held for:
- 2 quarters
- Latest activity:
- 2026 Q2
Polen Capital Management has been an institutional investor in Dianthus Therapeutics Inc (DNTH) since 2026 Q1. According to 2026 Q2 report, Polen Capital Management holds 9,333 shares with a market value of roughly $909.78K representing 0.01% of their equity portfolio. The fund/company first acquired DNTH in 2026 Q1, initially purchasing 4,119 shares. Since the initial investment, Polen Capital Management has made 1 more transaction in this position.
Does Polen Capital Management still hold DNTH?
Yes, Polen Capital Management continues to hold Dianthus Therapeutics Inc (DNTH). According to their 2026 Q2 report, they maintain a position of 9,333 shares valued at approximately $909.78K, representing 0.01% of their equity portfolio.
When did Polen Capital Management first invest in DNTH?
Polen Capital Management first invested in Dianthus Therapeutics Inc (DNTH) in 2026 Q1 at the reported quarter-end price of $83.92 per share, acquiring 4,119 shares in their initial purchase.
What is Polen Capital Management's average cost basis for DNTH?
Based on historical transaction data, Polen Capital Management's estimated cost basis for Dianthus Therapeutics Inc (DNTH) is approximately $91.50 per share. This represents their average reported price* across all buy transactions.
Estimated cost basis*
- Weighted AVG buy price:
- $91.50
DNTH transactions history by Polen Capital Management
2 results
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2026 Q2
|
0.01%
|
9,333
|
$97.48
|
$909,781
|
+126.58% (+5,214)
|
+0%
|
|
2026 Q1
|
0.00%
|
4,119
|
$83.92
|
$345,666
|
new
|
+0%
|
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.